-
November Foraging Guide: Edible Mushrooms and Critical Safety Protocols
-
German Auto Giants Face Existential Crisis as China Sales Plummet
-
Microsoft Updates Xbox PC App with 60% Faster Startup and Redesigned Interface
-
Cause of Death Revealed for 'Ellen' Producer Matthew Wright
-
Early Polar Vortex Disruption Creates Uncertain Winter Outlook for Pennsylvania
-
How to Enjoy Luxury Experiences on a Budget
-
Edmund Richardson Wins Baillie Gifford Prize for 'Alexander' Biography
-
Pakistan Demands Grant-Based Climate Finance at COP31 to Avoid Debt Trap
-
BYD Drops Rotating Screens in New Models Due to Tech Limits
-
E Pellicci Pop-Up at Selfridges Brings Back Nostalgic School Cake
-
Ryanair Flight from Rome Makes Emergency Landing in Lisbon After Bomb Threat
-
Coronation Street's Debbie Webster Steps Down as Dementia Storyline Intensifies
Featured
Last news
Trial opens in France over deadliest Channel migrant crossing disaster
Fourteen people suspected of links to trafficking networks went on trial in France on Tuesday over the loss of at least 31 people including a seven-year-old child in the Channel in 2021, the deadliest accident involving asylum seekers trying to reach the English coast.
Flights resume gradually in Indonesia after volcanic eruption
Major airports in Indonesia reopened on Tuesday days after a volcanic eruption had grounded flights, with authorities saying normal operations would resume gradually.
France tries 14 over deadliest Channel migrant crossing disaster
Fourteen people are to go on trial in France on Tuesday over the loss of 31 people including a seven-year-old child in 2021, in the deadliest small-boat crossing accident recorded in the Channel.
'The ber months': Christmas arrives early in the Philippines
At a city block-sized market in the Philippine capital, a platoon of plastic Santa Claus figures parachute from the ceiling of a shop already stacked high with Christmas decor despite the holiday being fully four months away.
Medicure Presents MEND-PNPO Phase 3 Study Design and Baseline Data at the 16th European Epilepsy Congress
WINNIPEG, MB / ACCESS Newswire / September 8, 2026 / Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH)(OTC PINK:MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, today announced that the design, rationale and baseline data from its MEND-PNPO Phase 3 study (ClinicalTrials.gov NCT04706013) are being presented at the 16th European Epilepsy Congress (EEC), taking place September 5-9, 2026, at the Megaron Athens International Conference Centre in Athens, Greece. MEND-PNPO is a pivotal trial evaluating MC-1 for the treatment of Pyridox(am)ine 5'-Phosphate Oxidase (PNPO) deficiency.
CV Sciences Welcomes Enactment of Federal Legislation Providing Additional Time for a Responsible, Science-Based Hemp Regulatory Framework
Legislation delays implementation of new federal hemp restrictions until December 11, 2026, preserving continued access to naturally derived hemp products
Protagonist Therapeutics Announces $300 Million Share Repurchase Program
NEWARK, CA / ACCESS Newswire / September 8, 2026 / Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today announced that its Board of Directors has authorized a share repurchase program under which the Company may repurchase up to $300 million of its outstanding common stock.
Appeals Court to Rule Soon on Marijuana Rescheduling as Billions in Cannabis Tax Benefits Hang in the Balance
As the D.C. Circuit prepares to decide whether the Justice Department lawfully moved state marijuana into DEA Schedule 3, experts warn that billions in anticipated tax benefits could unravel.
Who is the Best Cosmetic Surgeon in Washington State?
The Best Cosmetic Surgeon in Washington State is Dr. Sajan as Featured in Seattle Magazine and Seattle Met.
Who is the Best Facelift Surgeon in Seattle?
The Best Facelift Surgeon in Seattle is Dr. Santos at Seattle Plastic Surgery
Who Does the Best Breast Augmentation in Oklahoma?
The Best Breast Augmentation in Oklahoma Is Performed by Dr. Nuveen at Cosmetic Surgery Affiliates
Action Behavior Centers Celebrates 2026 Graduates, Sharing Family Stories and Research on School Transition Outcomes
Family stories highlight how ABC's BCBAs® help autistic children build the skills to support successful transitions into general education classrooms.
Who Does the Best Tummy Tuck in Jacksonville?
The Best Tummy Tuck in Jacksonville Is by Dr. Courtney Caplin at Cosmetic Surgery Affiliates
GenHealth.ai Raises $16.5 Million Series A to Build AI Agents That Run the Medical Back Office
Flare Capital Partners leads the round, bringing total funding to $30 million. GenHealth's AI agents complete intake, eligibility, prior authorization, billing, and denials inside the systems providers already use, with customers getting paid 30%+ more.
25-Year Mesothelioma Survivor Ellen Patton Partners With Mesothelioma Hope to Reach the Newly Diagnosed
Patton, the longest-known-living pleural mesothelioma survivor, joins the organization's patient resources as Mesothelioma Awareness Month begins.
StimCell Energetics Engages Stonegate Capital Markets as Non-Exclusive Advisor for Strategic Capital Market Transactions
VANCOUVER, BC / ACCESS Newswire / September 8, 2026 / StimCell Energetics Inc. (OTCQB:STME) ("StimCell" or the "Company"), a biotech pioneer targeting cellular energy to enhance wellness, anti-aging, and longevity, is pleased to announce that it has entered into an Advisory Services Agreement with Stonegate Capital Markets, Inc. ("Stonegate"), a Texas corporation, pursuant to which Stonegate will act as the Company's non-exclusive advisor.
Kartoon Studios Issues Letter to Shareholders Highlighting Strategic Transformation and Next Phase of Growth
BEVERLY HILLS, CA / ACCESS Newswire / September 8, 2026 / Kartoon Studios, Inc. (NYSE American:TOON) ("Kartoon Studios" or the "Company"), a global entertainment company creating, producing, distributing and licensing children's and family content, today announced that the Company filed its proxy statement with the U.S. Securities and Exchange Commission on Friday, September 4, 2026, which included a letter to shareholders from Andy Heyward, Chairman and Chief Executive Officer.
Aspire Biopharma Holdings, INC. Announces Corporate Name Change To Aspire-Lakewood Holdings, Inc.
ESTERO, FL / ACCESS Newswire / September 8, 2026 / Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) ("Aspire" or the "Company"), today announced that it has changed its corporate name from "Aspire Biopharma Holdings, Inc." to "Aspire-Lakewood Holdings, Inc." The name change is effective upon the filing of a Certificate of Amendment to the Company's Certificate of Incorporation with the Secretary of State of the State of Delaware. The Company's ticker symbol, "ASBP", will remain unchanged.
Now Available on Amazon: Neonorm Dog, Jaguar Health's Non-Prescription Product for Support of Normal Stool Consistency and GI Fluid Balance in Dogs
Neonorm® Dog extends Jaguar's existing Neonorm product franchise beyond foals and calves to provide dog owners with access to a plant-based product designed to support normal stool consistency and GI fluid balance in dogsJaguar expects Neonorm Dog to be available through other select online and animal health retail channels shortly, including Chewy
Medical Care Technologies Inc. (OTCID:MDCE) Shows Investors a Multi-Platform Company: AI Health, Enterprise Vision, Consumer Apps, and Revenue-Generating Subsidiaries
One AI Vision Core. Multiple Commercial Tracks Across Health, Agriculture, Foodservice, Consumer Wellness, Authentication, and Auctions.
Smith & Nephew Plc Announces Cash Tender Offer for 2030 Bonds Up To $250m
Smith+Nephew announces cash tender offer for up to $250 million of its outstanding 2.032% notes due 2030
Clinical Trial for an Oral Drug to Treat Ebola is Registered in the Pan African Clinical Trials Database and is Ready to Go, As the Largest Ebola Outbreak Continues to Expand in DR Congo
SHELTON, CT / ACCESS Newswire / September 8, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, announces that its Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for the Current Bundibugyo Ebolavirus and other Ebola viruses in the Democratic Republic of Congo ("DRC") was successfully registered in the Pan African Clinical Trials Registry (pactr.samrc.ac.za) database. The unique identification number for this clinical trial is PACTR202608748555077.
TripGift Launches Its Next-Generation Global Travel Value Platform
The 103-currency platform brings together global travel gift cards, rewards, incentives, programmable promotional vouchers and travel redemption across more than 180 countries.
Modular Medical to Participate in the iAccess Alpha Virtual Best Ideas Fall Investment Conference 2026 on September 15-16, 2026
SAN DIEGO, CA / ACCESS Newswire / September 8, 2026 / Modular Medical, Inc. ("Modular Medical" or "the Company") (NASDAQ:MODD), a commercial-stage medical device company preparing for the full commercial launch of its next-generation Pivot™ tubeless patch pump, today announced that its Chief Executive Officer, Jeb Besser, will present and host one-on-one meetings at the iAccess Alpha Virtual Best Ideas Fall Investment Conference 2026.
Food Culture Inc. Establishes Audit Committee and Advances Selection of a PCAOB-Registered Accounting Firm
Board establishes an audit committee chaired by independent director Alena Ivanova; Company receives proposals from three PCAOB-registered accounting firms and introduces a refreshed corporate mark
Lexaria Announces Exercise of Warrants for Approximately $5.9 Million in Gross Proceeds
KELOWNA, BC / ACCESS Newswire / September 8, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, today announced the entry into definitive agreements for the immediate exercise of certain outstanding warrants to purchase an aggregate of 453,969 shares of the Company's common stock originally issued by the Company on February 16, 2024, having an original exercise price of $32.78 per share, on October 16, 2024, having an original exercise price of $45.90 per share, on September 29, 2025, having an original exercise price of $20.55 per share and on December 16, 2025, having an original exercise price of $17.85 per share, at a reduced exercise price of $12.92 per share. The closing of the warrant exercise transaction is expected to occur on or about September 9, 2026, subject to satisfaction of customary closing conditions.
Who Does the Best Facelift in Florida?
The Best Facelift in Florida is Done by Dr. Sessa at Sarasota Surgical Arts
Who is the Best Female Cosmetic Surgeon in Florida?
The Best Female Cosmetic Surgeon in Florida Is Dr. Winnie Lee
Datameds, AI., and Tollo Health Partner with the NFL Alumni Association for Health Lives Here National Campaign Rollout
Leading Healthcare IT Company and Former NFL Players Will Work Together to Provide Rural Communities Access to Telehealth and Pharmacy-based Services Through Health Lives Here Mobile App
CPG Life Fund I Launches $20 Million Operator-Led CPG Fund
The operator-led CPG fund pairs investor capital with in-house formulation, manufacturing, Direct Store Delivery distribution, and TikTok Shop live selling across a target portfolio of 10 to 12 beverage, nutritional supplement, and beauty brands.
Equitech-Bio Expands Reagent Portfolio with New IgG Offering and Publication-Backed Product Validation from Bioz
PALO ALTO, CA / ACCESS Newswire / September 8, 2026 / Bioz, Inc., the scientific marketing platform that transforms peer-reviewed research into evidence-rich product experiences, today announced the continued expansion of its collaboration with Equitech-Bio, a trusted supplier of serum proteins, immunoglobulins, antisera, and other biological reagents for research, diagnostic development, and bioprocessing applications.
BioNxt Advances Sublingual Everolimus ODF for Organ Transplant Rejection with Initiation of Large-Animal Pharmacokinetic Study
VANCOUVER, BC / ACCESS Newswire / September 8, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is pleased to announce the advancement of its proprietary sublingual Everolimus oral dissolvable film ("ODF") program, initially targeting organ transplantation, with a comparative large-animal pharmacokinetic study.